CONCENTRATION OF INFLIXIMAB IN THE NON-INFLAMED MUCOSA AS A PREDICTOR FOR SECONDARY LOSS OF RESPONSE TO INFLIXIMAB FOR CROHN'S DISEASE PATIENTS: A 4-YEAR PROSPECTIVE STUDY

被引：0
|
作者：
Yoshihara, Takeo
Shinzaki, Shinichiro
Amano, Takahiro
Otake, Yuriko
Tani, Mizuki
Iwatani, Shuko
Tsujii, Yoshiki
Hayashi, Yoshito
Inoue, Takahiro
Watabe, Kenji
Iijima, Hideki
Takehara, Tetsuo
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1815
引用
收藏
页码：S1135 / S1135
页数：1
相关论文
共 50 条
  • [41] CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn's disease
    Li, Shaotang
    Wu, Hao
    Miao, Shouliang
    Huang, Chen
    Zhang, Yini
    Shao, Xinyi
    Chen, Chao
    Wu, Xiaoli
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2025, 369 (02): : 189 - 196
  • [42] Impact of JC Virus Antibody Testing in Patients with Crohn's Disease with Loss of Response to Infliximab: A Markov Model
    Scott, Frank I.
    Osterman, Mark T.
    McConnell, Ryan A.
    Lorusso, Monica
    Aberra, Faten
    Kerner, Caroline
    Lichtenstein, Gary R.
    Lewis, James D.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (12) : 2625 - 2633
  • [43] Perianal fistula closure with 4 weeks of adalimumab therapy in patients with fistulizing Crohn's disease and a history of intolerance or loss of response to infliximab
    Hinojosa, Joaquin
    Bastida, G.
    Vazquez, N.
    Guerrero, P.
    Castro, B.
    Fernandez, F.
    Gassull, M. A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S457 - S457
  • [44] Are Radiomic Spleen Features Useful for Assessing the Response to Infliximab in Patients With Crohn's Disease? A Multicenter Study
    Tang, Chao-Tao
    Yin, Fang
    Yin, Yitian
    Liu, Zide
    Long, Shunhua
    Zeng, Chun-Yan
    Chen, Yong
    Chen, You-Xiang
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (05)
  • [45] Switch to Adalimumab in Patients With Crohn's Disease Controlled by Maintenance Infliximab. the Prospective Randomized Switch Study
    Van Assche, Gert A.
    Vermeire, Severine
    Ballet, Vera
    Noman, Maja
    D'Haens, Geert R.
    Humblet, Evelien H.
    Claessens, Christophe
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2010, 138 (05) : S85 - S85
  • [46] INFLIXIMAB CAN BE DISCONTINUED FOR THE CROHN'S DISEASE PATIENTS WITH STRICT MONITORING OF FECAL CALPROTECTIN; PROSPECTIVE CONTROLLED STUDY
    Toyokawa, Tatsuya
    Fujita, Isao
    Horii, Joichiro
    GASTROINTESTINAL ENDOSCOPY, 2018, 87 (06) : AB371 - AB371
  • [47] Clinical and endoscopic features of secondary loss of response cases in patients with Crohn's disease treated with infliximab by top-down strategy: A case-control study
    Miyazaki, T.
    Fujimori, A.
    Koshiba, R.
    Fujimoto, K.
    Sato, T.
    Kawai, M.
    Kita, Y.
    Kamikozuru, K.
    Takagawa, T.
    Yokoyama, Y.
    Hida, N.
    Watanabe, K.
    Nakamura, S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S359 - S359
  • [48] C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease
    Toshifumi Hibi
    Atsushi Sakuraba
    Mamoru Watanabe
    Satoshi Motoya
    Hiroaki Ito
    Noriko Sato
    Toru Yoshinari
    Kenta Motegi
    Yoshitaka Kinouchi
    Masakazu Takazoe
    Yasuo Suzuki
    Takayuki Matsumoto
    Kazuhiko Kawakami
    Takayuki Matsumoto
    Ichiro Hirata
    Shinji Tanaka
    Toshifumi Ashida
    Toshiyuki Matsui
    Journal of Gastroenterology, 2014, 49 : 254 - 262
  • [49] Efficacy of Concomitant Elemental Diet Therapy in Scheduled Infliximab Therapy in Patients with Crohn's Disease to Prevent Loss of Response
    Kamata, Noriko
    Oshitani, Nobuhide
    Watanabe, Kenji
    Watanabe, Kimihiko
    Hosomi, Shuhei
    Noguchi, Atsushi
    Yukawa, Tomomi
    Yamagami, Hirokazu
    Shiba, Matsatsugu
    Tanigawa, Tetsuya
    Watanabe, Toshio
    Tominaga, Kazunari
    Fujiwara, Yasuhiro
    Arakawa, Tetsuo
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (05) : 1382 - 1388
  • [50] C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease
    Hibi, Toshifumi
    Sakuraba, Atsushi
    Watanabe, Mamoru
    Motoya, Satoshi
    Ito, Hiroaki
    Sato, Noriko
    Yoshinari, Toru
    Motegi, Kenta
    Kinouchi, Yoshitaka
    Takazoe, Masakazu
    Suzuki, Yasuo
    Matsumoto, Takayuki
    Kawakami, Kazuhiko
    Matsumoto, Takayuki
    Hirata, Ichiro
    Tanaka, Shinji
    Ashida, Toshifumi
    Matsui, Toshiyuki
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 254 - 262
12345